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INTRODUCTION
Epilepsy is probably a multietiological group of
diseases that has a high incidence worldwide (1). How-
ever, therapy for epilepsy is mostly palliative because
it is essentially aimed at alleviating the symptoms of
epilepsy, that is, seizures (2). In fact, seizures are the
phenotypic expression of a largely undefined cascade
of events involving functional and structural changes,
globally termed epileptogenesis (3), that may take
years to result in clinical expression (4,5). Seizures
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result from the recurrent firing of excitatory neurons
resulting from an imbalance toward a hyperexcitability
state (6,7). This repetitive firing leads to excessive
release of glutamate, the main excitatory neurotrans-
mitter in the central nervous system, and ultimately
to neuronal cell death (8–11), as illustrated by mesial
temporal sclerosis, a hallmark of one of the most
common adult forms of treatment-resistant epilepsy,
temporal lobe epilepsy (12,13).
The more popular antiepileptic drugs have been
developed as activity-dependent inhibitors of voltage-
sensitive sodium channels (14,15). These antiepileptic
drugs are mostly effective to control burst firing, which
is characteristic of a seizure rather than non–burst-like
nerve impulses. Incidentally, these drugs are also effect-
ive in attenuating the progression of seizures into status
epilepticus (16), in accordance with Gower’s concept
of “seizures beget seizures.” However, with progression
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of disease, there is a loss of efficiency of antiepileptic
drugs (2), probably because these drugs may not have
a direct effect on epileptogenesis or on neuronal cell
death (16). Another possible target for therapeutic inter-
vention to manage epilepsy might be restraining the
excessive release of glutamate that occurs during seizures
(17). This might be a promising strategy because gluta-
mate has a triple role in (i) mediating firing on hyper-
excitability of neuronal circuits (17–19); (ii) mediating
synaptic plasticity phenomena that involve both func-
tional and structural changes in neuronal circuits
(20); and (iii) mediating excitotoxicity and neuronal cell
death (21).
We are particularly interested in presynaptic mod-
ulatory systems that selectively modulate the release of
glutamate rather than of inhibitory neurotransmitters
such as GABA and that may be upregulated either by
seizures or by the epileptogenic process. In this review,
we consider three neuromodulatory systems that fulfil
these two criteria, namely the neuromodulatory systems
operated by kainate, adenosine, and neuropeptide Y
(NPY) receptors.
Kainate Receptors
Glutamate is the principal excitatory neurotransmit-
ter in the mammalian brain. In the hippocampus it
plays a major role in synaptic transmission, but in situ-
ations of excessive glutamate release, such as epilepsy
or excitotoxicity, glutamate may also be a key trigger of
neuronal dysfunction (22,23). Presynaptic ionotropic and
metabotropic glutamate receptors have been shown to
modulate the release of important neurotransmitters in
the brain (24,25). Among the identified presynaptic
glutamate receptors, the role of kainate receptors has
remained enigmatic for a long time. Now, an increasing
number of reports have contributed to open new
windows of knowledge about the functional properties
of presynaptic kainate receptors, in particular in relation
to hippocampal function and epilepsy. It has long been
known that administration of kainate induces seizures,
and indeed intraperitoneal or intracerebroventricular
injection of kainate in rats has been used as an animal
model of induction of temporal lobe epilepsy (26). On
the other hand, it is known that kainate receptors are
particularly abundant in the CA3 stratum lucidum
(27,28) and that the selective lesion of the mossy fiber
projections blocks kainate-induced seizures (28,29). In
fact, kainate receptors are emerging as one of the key
elements in hippocampal neuronal pacemaker activity
and epileptogenesis (30).
Five different kainate receptor subunits were
cloned (31,32). These subunits can form low-affinity
kainate receptors, GluR5, GluR6, and GluR7, or high-
affinity kainate receptors that includes KA1 and KA2
subunits. In addition, four GluR5 (GluR5-1, GluR5-2a,
GluR5-2b, and GluR52c) and two GluR7 (GluR7a and
GluR7b) alternative splice variants were also identified
(31,32). Moreover, mRNA editing at the Q/R site, in
the intracellular membrane loop between transmembrane
domains 1 and 3, contributes to the generation of two
alternative forms of GluR5, and editing at the same Q/R
site and at the I/V and Y/C sites in the transmembrane
domain 1 contribute to six different forms of GluR6 sub-
units (31,32).
Native ionotropic glutamate receptors, including
kainate receptors, may be constituted by tetrameric
organization of receptors subunits (33). The putative
diversity of the subunit organization at native receptors
can contribute to a significant variability of receptors
with different pharmacological properties.
In contrast to AMPA receptors, kainate receptors
are activated by lower concentrations of kainate as com-
pared with AMPA. The general agonist potency order
for kainate receptor activation is domoatekainateglu-
tamateAMPA for low-affinity kainate receptors,
and kainatedomoateglutamateAMPA for high-
affinity kainate receptors (34). However, in contrast to
the effect of kainate at AMPA receptors, the activation
of kainate receptors with kainate results in a desensi-
tizing response (35,36), and this desensitization is
prevented by concanavalin A (36,37). In recent years,
several agonists and antagonists selective for kainate
receptor subunits have been actively produced, increas-
ing the available tools for selective targeting of kainate
receptors (38,39).
Presynaptic and Postsynaptic Kainate Receptors in
the Hippocampus. The role of postsynaptic kainate
receptors in synaptic transmission in the hippocampus
was revealed as a result of the availability of efficient
and selective AMPA receptor antagonists (40,41). How-
ever, the activity of these receptors is normally masked
by the highly active AMPA receptors, and it is clearly
difficult to find a role for kainate receptors in mediating
fast neurotransmission (40–42). Similarly to what is
known for ATP/P2 and nicotinic receptors signaling
systems in the central nervous system, there is a para-
dox between robust receptor expression and inability to
clearly identify a role in neurotransmission, suggesting
that these receptors may behave as neuromodulatory sys-
tems (43). Interestingly, the activation of postsynaptic
kainate receptors was also shown only to occur upon the
stimulation at high-frequency of mossy fiber afferents
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(44). This frequency-dependent activation of postsynap-
tic kainate receptors may suggest that kainate receptors
are located at the periphery of the postsynaptic junction
or also may be regarded as the result of presynaptic
modulatory events initiated by glutamate-dependent
retrograde mechanisms at the presynaptic terminal.
Together, these observations strongly support the exis-
tence of a presynaptic target for kainate as a potential
element responsible for the biological effects of kainate
and domoate in the hippocampus. This putative kainate
receptor located presynaptically at mossy fiber terminals
is responsible for glutamate-induced glutamate release,
which may be responsible for the strong epileptogenic
and excitotoxic action of kainic acid at the CA3 area of
the hippocampus, was visionarily hypothesized two
decades ago (27).
Mossy Fiber Presynaptic Kainate Receptors, Glu-
tamate Release, and Epileptogenesis. Presynaptic mod-
ulation of glutamatergic neurotransmission by kainate
receptors has only recently reached relative consensus.
For more than two decades the clear identification of
the molecular target of the strong epileptogenic com-
pound kainate, in the hippocampus, remained undeter-
mined. However, in the last decade the cloning of
kainate receptor subunits (31,45) and the identification
of functional presynaptic kainate receptors by neuro-
chemical (34,46–48) and by electrophysiological tech-
niques (37,42,49–51) revealed an important molecular
target for presynaptic modulation of glutamate and
GABA release in the hippocampus.
The stratum lucidum of the CA3 area of the hip-
pocampus is the brain area with the highest density of
kainate receptors (30,52). Selective lesion of the mossy
fiber projections and immunohistochemistry studies
indicated that part of the kainate receptors in the stra-
tum lucidum are presynaptically located at mossy fiber
terminals (28,29,53). Following the selective lesion of
the mossy fiber projections or following neonatal -irra-
diation, causing granule cell death, a significant decrease
in the expression of high-affinity kainate binding sites
and reduction of kainate-induced epileptiform dis-
charges was observed (28–30). In agreement with the
hippocampal expression of kainate receptor subunits
(45,54) it may be expected that kainate receptors con-
taining GluR6, KA1, and KA2 subunits may play a
major role in mossy fiber synapses. Interestingly, GluR6
knockout mice are significantly less sensitive to kainate-
induced epilepsy and excitotoxicity, indicating a major
role for GluR6-containing receptors in the physiology
of mossy fiber synapses (44).
Presynaptic kainate receptors in the CA3 area of the
rat hippocampus directly modulate the intracellular free
Ca2 concentration (46,55) and induce the exocytotic
release of glutamate (47,56–58), contributing to the gen-
eration of a positive feedback mechanism responsible for
glutamate-induced glutamate release (27,34,58). This
focus of excitability in the hippocampus may play a
relevant role in LTP (56,59) and under pathological
noncontrolled activation, for example, domoic acid
intoxication (60), may contribute to the generation of
epilepsy (30) and excitotoxicity (44) of CA3 pyramidal
cells.
Subunit Composition of Mossy Fiber Presynaptic
Kainate Receptors. In spite of the very important findings
in the investigation of presynaptic kainate receptors at
the mossy fiber synapses, another major issue still lacks
consensus: the subunits involved in the organization of the
native receptors. The identification of the subunit compo-
sition of the presynaptic and postsynaptic kainate recep-
tors in hippocampal circuits may prove to be extremely
important because the development of selective drugs dif-
ferentially targeting presynaptic or postsynaptic receptors
may play a key role in the future development of new
antiepileptic strategies.
Studies with knockout mice for GluR6 and GluR5
indicate that GluR6 but not GluR5 subunits–containing
receptors play a role in the presynaptic modulation of
glutamate release from mossy fiber terminals (44,61).
Supporting a role for GluR6 subunit–containing kainate
receptors at CA3 nerve terminals, responsible for the
modulation of intracellular Ca2 and glutamate release,
our group determined the agonist potency order in increas-
ing the intracellular free Ca2 concentration: domoate
(EC50 0.16 M)kainate (EC50 0.86 M)AMPA
(EC50 43.04 M) (34,46,47).
Other studies indicate a preferential role for GluR5
subunit–containing receptors in the presynaptic effects of
kainate receptor agonists at mossy fiber synapses. It was
shown that ATPA, a GluR5 kainate receptor agonist,
depresses the mossy fiber–evoked synaptic transmission
(41,62,63). On the other hand, the GluR5 antagonist
LY382884 was able to inhibit the frequency-dependent
facilitation of mossy fiber transmission (56,57,63). The
latter studies indicate a role for GluR5 subunit–containing
presynaptic autoreceptor, at the mossy fiber terminals,
responsible for frequency-dependent facilitation of glu-
tamate release. However, it is essential to keep in mind
that the selectivity of kainate receptor agonists and antag-
onists was mainly tested in heterologous expression sys-
tems rather than in native receptors. Post-transcriptional
region-specific modification of kainate receptor subunits,
and the site-specific organization of kainate receptor
subunits into functional native receptors, may hamper the
interpretation about selectivity of the developed agonists
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and antagonists. Moreover, the distribution of mRNA for
the GluR5 subunit mainly in interneurons does not favor
the involvement of GluR5 subunits in the assembly of
presynaptic kainate receptors at mossy fiber terminals
(64). However, the distribution of mRNA is not
absolutely indicative of the location of the expression of
the receptor proteins, especially in the case of synaptic
receptors. So, one cannot exclude that the detected low
levels of mRNA for GluR5 in dentate granular cells may
account for the expression of GluR5 subunits at the
mossy fiber nerve terminals.
Recently we found that in the CA3 area of the
hippocampus GluR5, GluR6, and KA2 (but not KA1)
subunits are present in significant levels in the presy-
naptic fraction of the synaptic junctions, and so may
eventually account for the assembly of functional
kainate receptors in CA3 nerve terminals (Pinheiro et
al., unpublished observations). This study was based on
a method of separation of presynaptic and postsynaptic
proteins from the synaptic junctions (65) and identifi-
cation of the receptor subunits by Western blotting.
Using this strategy we recently identified surprisingly
high levels of presynaptic AMPA receptor subunits in
the rat hippocampus (66).
Depression of Excitatory Synaptic Transmission by
Presynaptic Kainate Receptors. The prevalent view of
kainate as a strong epileptogenic and excitotoxic
compound in the hippocampus has been challenged by
the finding that kainate receptor activation displays a
biphasic response in CA1 Schaffer collateral synapses
(42). At lower concentrations, kainate facilitates the
isolated NMDA receptors–mediated EPSCS, whereas
higher concentrations of kainate cause a depression of
the NMDA-mediated EPSCS through the activation of
presynaptic kainate receptors (42). Moreover, the same
authors also showed that activation of presynaptic
kainate receptors in rat hippocampal synaptosomes
inhibit the KCl-evoked release of glutamate (42).
Accordingly, a presynaptic kainate-receptor mediated
inhibition of the fEPSPs and EPSCs in the CA1 (62,67)
and CA3 areas (68,69) was reported.
The puzzling presynaptic inhibition mediated by
excitatory ionotropic receptors has been critically evalu-
ated, and the mechanisms underlying depression of glu-
tamatergic transmission and inhibition of glutamate
release are still the subject of debate, and no consensus
has yet been reached. Several different possibilities have
been tested, including (i) the inhibition of presynaptic
voltage-sensitive Ca2 channels (67,68); (ii) hyperpolar-
ization of nerve terminals as a result of influx of chloride
through GluR6 containing subunits (70); (iii) intracellu-
lar coupling of presynaptic kainate receptors to Gi/Go
proteins at glutamatergic nerve terminals (69); and (iv)
decrease of the quantal release, probably because of
sustained activation of presynaptic kainate receptors (61).
The apparent contradictory findings may reflect cell and
circuit variability in the hippocampus, as well as the
likely multifactorial involvement of the identified
processes in the inhibition of glutamate release.
Presynaptic Kainate Receptors and GABA Release.
Presynaptic kainate receptors on GABAergic terminals
that are able to reduce the evoked release of GABA and
to depress the inhibitory synaptic transmission, in the
hippocampus, have also been identified by several groups
(48,50,51). However, the mechanism by which kainate
receptors depress inhibitory synaptic transmission has
been a matter of conflicting interpretation (30,32).
A group of reports attribute to presynaptic kainate
receptors a direct presynaptic inhibition of the evoked
release of GABA and depression of inhibitory transmis-
sion (32,48,50,51). The functional coupling between
receptor activation and inhibition of GABA release
inhibition was claimed to involve inhibitory G proteins
(71–74), an interpretation based on the sensitivity to
pertussis toxin of kainate receptor–induced depression
of inhibitory synaptic transmission (71–73). Moreover,
both protein kinase C and protein kinase A were shown
to be involved in the downstream intracellular execution
mechanisms leading to inhibition of GABA release
(73,74). Other groups postulated that the kainate recep-
tor–mediated depression of inhibitory synaptic transmis-
sion can be caused by a massive neuronal depolarization
resulting from generation of ectopic action potential in
axons (75) or, alternatively, caused by activation of GluR5
and GluR6-containing postsynaptic kainate receptors in
interneurons (30,76–79), consistent with the expression of
both subunits at a population of hippocampal interneurons
(80). It was hypothesized that the resulting release of
GABA from interneuronal terminals decreases the input
membrane resistance of CA1 pyramids due to hyperacti-
vation of GABAA receptors (30,76). Alternatively, at the
presynaptic level GABA may activate presynaptic
GABAB receptors (81) or the repetitive firing of interneu-
rons may cause exhaustion of releasable synaptic vesicles
containing GABA (30).
Recently, new findings challenged our knowledge
about functional properties of presynaptic kainate recep-
tors. It was shown that the direct activation of GluR6-
containing (but not GluR5-containing) presynaptic
kainate receptors increases the efficiency of GABAergic
synapses (79,82–84). Interestingly, as shown for gluta-
matergic synapses, at GABAergic synapses a biphasic
response of presynaptic kainate receptors was also
found, with low agonist concentration potentiating and
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high agonist concentration inhibiting the release of
GABA (83).
A general consensus is now on the borderline of
acceptance
A. “Presynaptic kainate receptors efficiently modulate
the release of glutamate and GABA and synaptic
transmission in a biphasic manner”.
B. “Low concentrations of kainate receptor agonists
potentiate, whereas high concentrations inhibit the
release of neurotransmitters and synaptic transmission”
C. “Potentiation of the neurotransmitter release is
caused by depolarization involving the influx of
cations through the receptor channel.”
D. “Inhibition of neurotransmitter release may be
due to:
1. Interneuron depolarization caused by activa-
tion of postsynaptic kainate receptors and
massive GABA release, which downregulates
GABAergic synapses.
2. Activation of presynaptic kainate receptors may
result in the inhibition of glutamate and GABA
release by involving:
a) Coupling to metabotropic inhibitory path-
ways.
b) Hyperpolarization resulting from chloride
influx.
c) Inhibition of voltage-sensitive Ca2 channels.
d) Exhaustion of ready-to-fuse pool of synaptic
vesicles.
3. A sum of some of the above indicated mechan-
isms in a regional and circuit-specific fashion.”
E. Kainate is a potent excitatory neurotoxin. Although
some mechanisms compatible with a kainate recep-
tor–mediated decrease in excitability were identified,
it is not clear how they are physiologically relevant.
It is now clear that the prevalent effect of presynap-
tic kainate receptor activation in the CA3 area of the
hippocampus is strongly excitatory and can be
involved in synaptic plasticity and in dysfunction
such as epileptogenesis and excitotoxicity. The
development of new pharmacological tools that can
selectively target CA3 presynaptic kainate receptors
may represent an important step in the treatment of
these disorders.
Adenosine Receptors
Adenosine is a prototypical neuromodulator
because it controls the efficiency of synaptic transmis-
sion but is neither released in a transmitter-like fashion
nor does it act vectorially to transmit information
between neurons (85,86). The most evident effect of
adenosine in the central nervous system is its ability to
refrain synaptic transmission and neuronal excitability
(87–89). This effect is due to the activation of inhibitory
A1 receptors, the most abundant of the four (A1, A2A,
A2B, and A3) metabotropic adenosine receptors in the
central nervous system (85,86).
Extracellular Adenosine Metabolism. The extracel-
lular levels of adenosine are directly related with the
degree of activity of neuronal circuits. Thus, with low
frequencies of nerve stimulation (i.e., that do not trigger
short-or long-term plasticity phenomena, typically below
0.1 Hz), there is a tonic on-going adenosine A1 receptor-
mediated inhibition of synaptic transmission (90) and the
levels of extracellular adenosine raise with single pulsed
stimulation of the preparations (91). Extracellular adeno-
sine can result from the extracellular catabolism of ATP
that can be released together with neurotransmitters and
from other compartments in the brain (43). This released
ATP can then be converted into adenosine through the
action of a series of ectonucleotidases (92,93). Adenosine
can also be released as such through bidirectional and non-
concentrative nucleoside transporters (85,94) in stressful
situations that cause a minor decrease in intracellular ATP
concentrations (3–5 mM) resulting in dramatic changes in
intracellular adenosine concentrations (basal concentration
of about 50 nM) (85). Note that these metabolic imbal-
ances may be localized in discrete subcellular compart-
ments, such as dendrites, because it is well established that
the activation of excitatory amino acid receptors increases
the extracellular levels of adenosine (94). However, the
main role of these nucleoside transporters is to clear up
extracellular adenosine, which is then intracellularly either
rephosphorylated into AMP, through adenosine kinase (in
neurons), or deaminated into inosine, through adenosine
deaminase (mainly in astrocytes) (85,94). Thus the exis-
tence of two pathways to form extracellular adenosine is
probably due to the fact that adenosine fulfils two parallel
functions, as a neuromodulator in nonstressful situations
(in which extracellular adenosine is probably mainly
formed from released ATP) and as a homeostatic modu-
lator (where extracellular adenosine is probably released
as such) (85).
Effects of Adenosine A1 Receptors on Neuronal
Excitability. The inhibitory effect of adenosine is par-
ticularly evident in excitatory rather than inhibitory
neurons in the brain (85). In fact, in some brain areas,
such as in the hippocampus, the activation of A1 recep-
tors only directly inhibits excitatory rather than
inhibitory synpases (95,96). The inhibition by adeno-
sine of synaptic transmission essentially results from a
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presynaptic effect (97,98), namely to the ability of A1
receptors to inhibit the evoked release of glutamate (99).
This A1 receptor–mediated control of glutamate release
may involve either an inhibition of calcium entry
through voltage-sensitive calcium channels (100–102) or
a decreased affinity of the calcium sensor responsible
for triggering neurotransmitter release (103–106).
The effects of adenosine on neuronal function are
not limited to its ability to control the evoked release
of glutamate. In fact, A1 receptors are also located post-
synaptically and nonsynaptically in neurons (107). Post-
synaptically, A1 receptors can inhibit NMDA receptors
(108,109) and voltage-sensitive calcium channels
(110,111). This is probably the basis for the ability of
adenosine to control dendritic integration, namely
synaptic plasticity phenomena (112). Furthermore, the
A1 receptor–mediated control of NMDA receptor func-
tion may be a key feature of the neuroprotective effects
of adenosine (113,114). Adenosine also decreases neu-
ronal firing (88,89) acting nonsynaptically mainly
through activation of potassium channels leading to neu-
ronal hyperpolarization (115–117). Probably the latter
effect plays a key role in the A1 receptor–mediated
control of neuronal circuits, being more evident in
situations of burst firing (88).
Anticonvulsant Properties of Adenosine A1 Recep-
tors. A series of studies have shown that administration
of adenosine and of A1 receptor agonists display anti-
convulsant properties in different animal models of
epilepsy (118–133). Likewise, adenosine and A1 recep-
tor agonists are also anticonvulsants in in vitro slice
models of epilepsy (90,134). In vitro studies have been
instrumental to support the idea that the anticonvulsant
effect of adenosine may result in part from an inhibi-
tion of the evoked release of glutamate, but mainly from
the hyperpolarizing action of adenosine mediated by
activation of potassium channels (90,124,135). Thus
adenosine is particularly effective in controlling sec-
ondary after-discharges and in refraining the rate of
interictal spiking in brain slice models of epilepsy
(132,135,136). Likewise, in animal models of epilepsy,
adenosine and A1 receptor agonists are able not only to
increase the threshold for seizure induction but also con-
tribute to seizure arrest (132,133).
The relevance of the adenosine neuromodulatory
system for the control of seizures is best illustrated by
the proposal that adenosine might be an endogenous
anticonvulsant (137). This implies that endogenous
adenosine would exert a tonic anticonvulsant effect.
This has received direct experimental confirmation by
the proconvulsant action of adenosine receptor antago-
nists (119,120,122,131,138–144). However, except in
the CA3 region of the hippocampus where adenosine
receptor antagonists cause a persistent paroxysmal activ-
ity (90,145–147), the blockade of adenosine receptors is
by itself not sufficient to trigger seizures in naive ani-
mals or preparations (132), and adenosine receptor
antagonists do not seem to alter the course of a seizure
per se (144). However, adenosine receptor antagonists
can prolong epileptic seizures (139,140,144) and can
convert a pattern of recurrent seizures into status epilep-
ticus (122,131).
The extracellular levels of adenosine raise abruptly
with patterns of stimulation that induce seizures
(148–154). This increase in extracellular adenosine starts
within 10 s of stimulation and peaks at 60–180 min
(144,148,150,153). Most importantly, the extracellular
levels of adenosine remain elevated postictally and, in
keeping with the hypothesis that adenosine is likely to
be responsible for much of postictal depression, antago-
nists of adenosine receptors can reduce the duration of
postictal depression (144,155).
Another potential benefit of adenosine and adeno-
sine A1 receptor agonists for the management of epilep-
tic complications is their neuroprotective properties
(113,156). In fact, under different stressful situations,
adenosine and adenosine A1 receptor agonists can atten-
uate the outcome of stress-induced neuronal cell death
(113,156), an effect that may be of interest in view of
the extensive neuronal cell death occuring as a conse-
quence of seizure activity (8–11).
Impact of Seizures and Epilepsy on Adenosine
Neuromodulation. The above presented evidence indi-
cates that adenosine may exert a tonic anticonvulsant
effect but also shows that exogenously added adenosine
or A1 receptor agonists can produce an even greater
anticonvulsant effect. This suggests that the adenosine
neuromodulatory system has a potential therapeutic
interest to control seizures. However, because adenosine
receptor agonists do not efficiently cross the blood
brain barrier (157) and display evident side effects,
including profound reductions in blood pressure and
heart rate, hypothermia, sedation, and motor depression
(121,158,159), it seems more reasonable to attempt to
increase the extracellular levels of adenosine by con-
trolling its clearance and metabolism rather than directly
activating A1 receptors. In fact, in spite of the large
seizure-induced increase in the extracellular levels of
adenosine, further increasing the levels of extracellular
adenosine (160) by inhibition of adenosine transporters
(134,141,161,162), adenosine kinase (162,163), or
adenosine deaminase (162) increases the threshold for
seizure induction. Likewise, increasing the number
(164) or the affinity of A1 receptors (165) also causes
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the same effect. These observations also lead to the idea
that repeated seizures may influence the adenosine neu-
romodulatory system.
In fact, the density of adenosine A1 receptors is
enhanced after acute seizure induction (170–172) but is
reduced after chronic seizure induction (128,166–169).
This is in agreement with the requirement of higher doses
of A1 receptor agonists to produce anticonvulsant effects
as status epilepticus progresses (131), possibly because
of the reduction in the efficacy of A1 receptor agonists
observed in fully kindled rats (173). In parallel, there is
a complex change in the extracellular metabolism of
purines. Thus, after seizures, there is an increased release
of ATP (174), which may also play a prominent role
in seizure control (175), a decrease in ecto-ATPase
(and/or ecto-ATP diphosphohydrolase) activity(ies)
(173,176–178), and a marked increase in the activity of
ecto-5-nucleotidase (173,179), the enzyme responsible
for the formation of adenosine from adenine nucleotides
(92). Finally, both the density (180) and the efficiency
of nucleoside transporters (173) are decreased upon
seizure induction. Overall, these modifications would
lead one to anticipate a greater formation and longer half-
life of ATP-derived adenosine. However, it is precisely
the opposite that is observed, that is, the tonic inhibition
by adenosine of hippocampal synaptic transmission or
synaptic plasticity has a considerably lower amplitude
in fully kindled rats (173). This makes sense in light
of the hypothesis that ATP-derived adenosine leads to a
preferential activation of facilitatory A2A rather than
inhibitory A1 receptors (85,181).
Adenosine A2A Receptors: A New Target for
Epilepsy? The role of A2A receptors in epilepsy is still
ill-defined, mainly because the more selective adenosine
A2A receptor agonist CGS 21680 has a poor selectivity
toward extrastriatal A2A receptors (182). In fact, mixed
effects of purported A2A receptor agonists on seizure
outcome have been reported (183–189). However,
recent reports described robust anticonvulsant effects of
A2A receptor antagonists in the threshold of seizure
induction (190,191). Likewise, adenosine A2A receptor
knockout mice also display a higher threshold for
seizure induction in different models of epilepsy
(190,191). This protective effect of A2A receptor block-
ade or inactivation parallels the general neuroprotective
effects of A2A receptor blockade in different stressful
situations (192–199).
The mechanism by which A2A receptors control
neuronal dysfunction is still poorly understood, espe-
cially because of the low density of A2A receptors in
extrastriatal regions of the brain (200). However, the
recent observations that stressful situations lead to an
increased expression and density of A2A receptors (201)
may help in understanding the efficiency of A2A recep-
tor antagonists in stressful situations based on the
hypothesis of stress-induced gain of function of A2A
receptors. Interestingly, we have recently observed that
there is an increased density of A2A receptors in the cere-
bral cortex and hippocampus of fully kindled rats (202).
A particular impact of A2A receptor blockade in epilepsy
may also be anticipated based on the ability of A2A
receptor blockade to blunt the effect of brain-derived
neurotrophic factor (BDNF) (203). A and conversely in
the ability of A2A receptor agonists to trigger TrkB recep-
tor activation even in the absence of BDNF (204). In
fact, seizures induce a robust increase in the expression
of the BDNF gene (205), and a striking reduction of
development of kindling was found in BDNF heterozy-
gotes (206). Also, infusion of TrkB receptor bodies (pro-
teins that selectively bind ligands of TrkB receptors such
as BDNF) in the ventricles of mature animals limit the
development of kindling (207).
Although still requiring considerable experimental
confirmation, these preliminary observations open a
new conceptual possibility to interfere with seizure
induction, and eventually epileptogenesis, and seizure-
induced neuronal degeneration based on the blockade
of adenosine A2A receptors. This is particularly inter-
esting given that lower doses of A2A receptor antagon-
ists seem to be required to hit central versus peripheral
A2A receptors (193,197,198), that the central effects
of A2A receptors antagonists seem to stable over time
(208–210), and that there is an increased density and
functional relevance of A2A receptors in the neocortex
and in the limbic cortex upon aging (211,212) when
epilepsy complications are prevalent.
Neuropeptide Y and Its Receptors
Neuropeptide Y (NPY) is a member of a peptide
family that also includes peptide YY (PYY) and
pancreatic polypeptide (PP). This family of peptides is
sometimes referred as the pancreatic polypeptide family,
because PP was the first of these peptides to be discov-
ered (213). However, NPY has remained much more
conserved during evolution than PP, and this family of
peptides should be more appropriately called NPY family
(214,215). In mammals, NPY is mainly expressed in
neuronal tissue (216), whereas PYY is primarily expressed
in the gut endocrine cells (217). In contrast, PP seems to
be exclusively pancreatic (217). Indeed, NPY has neuro-
transmitter properties (218), while PYY and PP act as
hormones in an endocrine and exocrine fashion, that is,
by regulating pancreatic and gastric secretion (217).
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The members of the NPY family (NPY, PYY, and
PP) act upon the same family of NPY receptors (219).
Five distinct NPY receptors have been cloned, and
sequence comparisons show that receptors Y1, Y4, and
Y6 are more closely related to each other than to the
receptors Y2 and Y5 (220). Among the cloned recep-
tors, the Y1, Y2, Y4, and Y5 receptors represent fully
defined subtypes, whereas no functional correlate of the
cloned y6 receptor has been reported to date. Moreover,
the subtypes Y1, Y2, and Y5 preferentially bind NPY
and PYY, and Y4 preferentially binds PP. All the recep-
tors of the family share the characteristics of seven
transmembrane domain-G–protein coupled receptors. In
particular, Y receptors act via pertussis toxin–sensitive
G-proteins, such as members of the Gi and Go family,
and are capable of mediating the inhibition of adeny-
late cyclase and, consequently, the inhibition of
cAMP accumulation in tissues and cells. However, the
resulting functional effects depend on the system being
studied.
NPY and Epilepsy. Emerging evidence points to an
important role for NPY in the regulation of neuronal
activity both under physiological conditions and during
pathological hyperactivity such as that occurring during
seizures. Following acute seizures, there is an increase
in NPY levels in the neurons of some cortical and lim-
bic areas, particularly in the hippocampus, amygdala,
and frontal, pyriform, and entorhinal cortices (221,222).
In the hippocampus, NPY is constitutively expressed in
GABA interneurons. Seizures have been repeatedly
shown to enhance NPY levels both in these inhibitory
interneurons and in the excitatory granule cells and
mossy fibers that do not normally contain the peptide
(221–224). Indeed, expression of NPY in granule cells
is induced by stimulation of metabotropic and ionotropic
glutamate receptors, which suggests that excitatory glu-
tamatergic neurotransmission regulates the expression of
NPY. This neuropeptide can inhibit epileptiform activ-
ity in the rat hippocampus in vitro, which can be due
to inhibition of glutamate-mediated synaptic transmis-
sion in areas CA1 and CA3 (225), or in epileptic humans
dentate gyrus (226). Moreover, Van den Pol et al. (227)
have demonstrated that glutamate-dependent activity is
necessary for NPY to depress the intracellular Ca2 con-
centration and the electrical activity of neurons. In ani-
mals lacking NPY, seizures induced by excessive exci-
tation (e.g., kainic acid) were not controlled in a
“normal” manner, resulting in prolonged seizure activ-
ity and death in most NPY-deficient mice (228). Also,
transgenic rats overexpressing NPY, especially in the
CA1 area of the hippocampus, were less susceptible
to epileptogenesis because they showed a significant
reduction in the number and duration of electroen-
cephalographic seizure activity induced by kainate
(229). Given that NPY inhibits excitatory neurotrans-
mission in normal hippocampus (230) and that exogen-
ous administration of NPY prominently suppresses
limbic seizure activity induced by kainic acid (231), one
possibility is that NPY acts as an endogenous anticon-
vulsant agent by dampening the excessive excitation
associated with seizures.
Following seizures, the increase of Y1 receptor
mRNA in the hippocampus is widespread, rapid, and
very transient, whereas there is a major increase of Y2
receptor mRNA expression and a rapid and transient
increase of Y5 receptor mRNA in the dentate granule
cell layer (232). Indeed, the increase in Y2 receptor
binding in the hilus of the dentate gyrus is associated
with an enhanced NPY release after kainate injection
(233). However, this upregulation is always dependent
on the duration and spread of the epileptiform activity.
Some studies preceding the discovery of Y5 receptors
have only implicated Y2 or Y1 receptors in the modu-
lation of anticonvulsant actions of NPY in the rat hip-
pocampus (234,235). There is some evidence showing
that the activation of Y2 or blockade of Y1 receptors,
respectively, reduce kainate-induced seizures (236), but
the pharmacological profile of centrally administered
NPY analogues capable of inhibiting kainate-induced
seizures in rats also suggests the involvement of Y5
receptors (231).
NPY and Excitotoxicity. NPY acting on Y1 receptors
causes inhibition of Ca2 influx through N-type channels
into the somata and dendrites of granule cells in the
hippocampus (237), whereas an excitatory component of
NPY appears to be mediated by postsynaptic Y1 receptors
(238). The activation of postsynaptic Y1 receptors has a
depolarizing action on granule neurons when applied to
their dendritic projection in the stratum moleculare (239).
Moreover, NPY acting on Y2 receptors inhibits excitatory
(glutamatergic) synaptic transmission (230) onto CA3
pyramidal cells (237). Recently, a presynaptic Y2 recep-
tor was also identified as the NPY receptor responsible
for the NPY-mediated inhibition of glutamate release in
the CA1 subregion (240,241).
Electrophysiological and pharmacological studies
have revealed that NPY acts predominantly through Y2
receptors and inhibits glutamate release (221,241,242)
by inhibiting Ca2 influx into presynaptic nerve termi-
nals through several types of Ca2 channels (243).
Moreover, we recently showed that the inhibition of
glutamate release in the hippocampus is mediated by the
activation of Y1, Y2, and Y5 receptors in the dentate
gyrus and CA3 subregion and by the activation of Y2
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receptors in the CA1 subregion (241,243). Our results
also strongly suggest the involvement of L-, N-, and
P/Q-type channels in the inhibition of [Ca2]i and
glutamate release mediated by NPY receptors in the hip-
pocampus, showing that the intracellular mechanism of
coupling between NPY receptor activation and inhibi-
tion of exocytosis involves the influx of Ca2 through
different voltage-gated calcium channels (243). More-
over, in the hippocampus the Y1 receptors seem to act
both presynaptically and postsynaptically, whereas the
Y2 receptors act mainly at presynaptic nerve terminals,
showing however activity at dendrites (243). Y5 recep-
tors also seem to play an important role in the control
of the glutamatergic mechanism in the hippocampus.
Woldbye et al. (231) showed that these receptors inhibit
kainic acid seizures, but others demonstrated that Y5
receptor–deficient mice do not exhibit spontaneous
seizure-like activity (244). Recently, Guo et al. (245)
also showed that the Y5 receptor subtype plays a crit-
ical role in modulation of hippocampal excitatory trans-
mission at the hilar-to-CA3 synapse in the mouse, but
does not suppress epileptiform activity in the CA3 hip-
pocampal area. Moreover, we have also presented func-
tional evidence for the interaction between Y1 and Y2
or Y2 and Y5 receptors. The simultaneous activa-
tion of both receptors did not result in a potentiation of
the inhibition of glutamate release and [Ca2]i changes
mediated by each receptor individually (243). These
observations strongly suggest the formation of
oligomers of Y1 and Y2 or Y2 and Y5 receptors, with a
pharmacology very similar to that observed for the Y2
receptors. It was also recently shown that NPY recep-
tors may associate in dimers (246), further supporting
our proposal of direct functional and physical interac-
tion between different NPY receptors.
The strong efficiency of Y1, Y2, and Y5 receptors
in modulating the exocytotic release of glutamate led us
to investigate a neuroprotective role of NPY receptor
activation against excitotoxic insults. Recently, we iden-
tified a robust neuroprotective effect of Y1, Y2, and Y5
receptor activation against neuronal cell death caused by
aggression associated with selective activation of
AMPA or kainate receptors in organotypic cultures of
rat hippocampal slices (247).
So, it seems that Y1, Y2, and Y5 receptors play an
important neuroprotective role during excitotoxic con-
ditions and epilepsy, and the identification of which
NPY receptors mediate the inhibitory or excitatory
effects of NPY may be important for pharmacological
targeting in several pathological conditions associated
with glutamate receptor hyperactivation and dysfunc-
tion. Moreover, the putative formation of oligomers of
NPY receptors can give us additional and important
information relevant to the development of new drugs
for the treatment of epilepsy.
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